ASE Technology Holding Co Ltd vs Boston Scientific Corporation — how do they compare? ASE Technology Holding Co Ltd trades at $41.02 (market cap $92.88B), while Boston Scientific Corporation trades at $44.99 (market cap $66.54B). The key difference: ASE Technology Holding Co Ltd is the larger of the two by market cap, and ASE Technology Holding Co Ltd pays a 0.98% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| ASX | BSX | |
|---|---|---|
Market Cap | $92.88B | $66.54B |
Sector | Technology | Health |
52-Week High | $45.12 | $108.14 |
52-Week Low | $9.50 | $42.68 |
Enterprise Value | $97.32B | $76.12B |
Dividend Yield | 0.98% | — |
Signals from Pluang's Aura AI — not financial advice
ASE Technology Holding (ASX) trades at $42.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong support at $41. The company reported revenue of $645.39B in 2025, with net income of $40.02B and a net margin of 6.95%. Recent earnings beats and a dividend announcement for H2-26 of $0.42 per share highlight operational strength. Analyst sentiment is positive, with 80% recommending Buy, driven by AI-driven packaging demand and LEAP business growth.
Outlook remains favorable due to robust earnings momentum and expanding margins in advanced packaging, though high valuation ratios (P/E of 66.95) and debt levels pose risks. The stock's proximity to its 52-week high suggests limited near-term upside without further catalysts. Key risks include execution challenges in capacity expansion and macroeconomic sensitivity.
Boston Scientific (BSX) trades at $44.77, down 0.49% with a bearish technical signal despite strong fundamentals. The company shows robust revenue growth from $12.7B in 2022 to $20.1B in 2025, with net income margin expanding to 17.29%. Recent earnings beats and a 88% analyst buy rating contrast with the stock's 60% decline from its 2025 high, creating a significant valuation gap versus the $72.38 consensus target.
BSX presents a compelling value opportunity with attractive valuation metrics (P/E 18.73, P/S 3.25) and strong profitability, though investors face near-term technical weakness and competitive pressures in key segments like electrophysiology. The stock's current price represents a 38% discount to analyst targets, suggesting substantial upside potential for patient investors despite recent market skepticism.
Trailing returns across standard periods
Latest headlines on both assets
ASE Technology Holding Co Ltd is a semiconductor assembly and testing firm. The company operates in segments: Packaging, Testing, and Electronic Manufacturing Services. Of these, packaging services contribute the most revenue. It involves packaging bare semiconductors into completed semiconductors with improved electrical and thermal characteristics. The Testing Segment includes front-end engineering testing, wafer probing, and final testing services. In the EMS segment, the company designs manufacture and sells electronic components and telecommunication equipment motherboards. The company is based in Taiwan but garners over half its sales from firms in the United States.
Read more on ASX →Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →